For the study, Morgans and her coauthors evaluated data for 284 patients. Of the cohort, 37% had known PSADT and 63% had unknown PSADT. More patients with known PSADT had characteristics of more ...

Initial data from the TALAPRO-2 trial were shared in 2023, showing that the combination of enzalutamide plus talazoparib extended radiographic progression-free survival (rPFS) vs enzalutamide alone.

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD. Six-month ...

An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced ...

“Interestingly, the patients that were more likely to follow-up were those patients that were seen and established within our urology clinic,” says Christina B. Ching, MD. In this interview, Christina ...

"It is important for us to ask patients whether they want to intensify or not, and not make assumptions," says Alicia Morgans, MD, MPH. In this video, Alicia Morgans, MD, MPH, shares insights from the ...

"It was a really interesting paper to develop and write, because over the past decade, there's been such a paradigm shift in the treatment of prostate cancer," says Dr Louise Kostos. In this video, Dr ...

"At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months," says Jacob A. Moyer, BS. Moyer: Since nadofaragene firadenovec was approved in ...

"[The lack of] a battery makes it ultra small. That's really important," says Colin Goudelocke, MD. In this video, Colin Goudelocke, MD, describes the advantages of a batteryless neurostimulator ...

“Five years after telehealth suddenly became a routine part of care for most Americans, we show that it has not led to runaway utilization or spending. This kind of in-depth analysis can inform its ...

Experts discuss the frequency of cystectomy use in patients with non–muscle-invasive bladder cancer (NMIBC) and how often patients are requesting bladder-sparing treatments.

Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems ...